GSK initiates Phase III programme of gepotidacin antibiotic
How to Treat Urinary Tract Infections (UTI): GSK's Gepotidacin May Work - Bloomberg
Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase | ACS Infectious Diseases
Intracellular concentration-response curves of gepotidacin (GEP)... | Download Scientific Diagram
Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants | SpringerLink
Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants | Antimicrobial Agents and Chemotherapy
Antibiotics | Free Full-Text | Antibacterial Activity of the Novel Drug Gepotidacin against Stenotrophomonas maltophilia—An In Vitro and In Vivo Study
Gepotidacin for Urinary Tract Infection Clinical Trial 2023 | Power
Gepotidacin (GSK2140944) Demonstrates Similar Safety and Pharmacokinetics in Adults and Adolescents (12 to ˂18 years) | GSK
Safety Trial of New Antibiotic - YouTube
With endpoints already met, GSK halts trial into new antibiotic
Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | Antimicrobial Agents and Chemotherapy
Dose Selection for Phase 3 Studies Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | GSK
GSK to submit drug application for new antibiotic to US FDA - PMLiVE
Overview of microbiome dynamics during gepotidacin Phase 2a clinical... | Download Scientific Diagram
Antibiotics | Free Full-Text | Pharmaceutical Approaches on Antimicrobial Resistance: Prospects and Challenges
Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea | Sexually Transmitted Infections
Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | Antimicrobial Agents and Chemotherapy
Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase | ACS Infectious Diseases
Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose- Ranging, Single-Oral Dose Eva
Gepotidacin: New antibiotic appears to be effective against UTIs, company says | CNN
Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | Antimicrobial Agents and Chemotherapy
New Antibiotic for Urinary-Tract Infections Found Effective in Trials - WSJ
GSK stops two Phase 3 studies for gepotidacin stopped early
Gepotidacin (GSK2140944) | Cas# 1075236-89-3 - GlpBio
